je.st
news
Merck Announces First-Quarter 2016 Financial Results
2016-05-05 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89 Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77 First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C Genotypes 1 or 4 Infection Advanced KEYTRUDA Development Program sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer Breakthrough Therapy Designation Granted for Classical Hodgkin Lymphoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2016. Our first quarters performance sets us on a good course for the year, said Kenneth C. Frazier, chairman and chief executive officer, Merck. We remain focused on advancing our pipeline and driving the commercial success of our key launches and inline medicines and vaccines. Financial Summary Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Category:Biotechnology and Pharmaceuticals